# To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

> **NCT06948539** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Breast Cancer
- Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** TQB2101 for injection

## Key facts

- **NCT ID:** NCT06948539
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06948539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06948539, "To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT06948539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*